Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on November 23, 2022. The report addresses a corporate governance matter regarding the composition of the company's Audit Committee and its compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance rather than financial performance.
Material Changes
The material change reported is the removal of Dr. Karin Hehenberger from the Audit Committee due to a determination that she did not qualify as independent under Nasdaq Listing Rule 5605(c)(2)(A)(ii). Consequently, the Board appointed Dr. Caley Castelein to the Audit Committee to restore compliance. The Audit Committee now consists of Emma Reeve (Chair), Richard Maroun, and Dr. Caley Castelein.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business operations. The primary risk addressed was the potential delisting or failure to satisfy continued listing rules due to non-compliance with audit committee independence requirements. Management believes the company has regained compliance following the personnel changes.
Investor Verification Checklist
- Verify the current composition of the Audit Committee to ensure all members meet Nasdaq independence requirements.
- Confirm that the company has received formal confirmation from Nasdaq regarding the restoration of compliance.
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.
- Note the discrepancy between the requested company name (Whitehawk Therapeutics) and the filing registrant (Aadi Bioscience).